Why Are Drugmakers Racing to Acquire ADC Payload Platforms?

Novartis announced on July 6, 2026 that it has agreed to acquire Myricx Bio in a deal aimed at strengthening its oncology pipeline with a new class of antibody-drug conjugate (ADC) payload.¹ The transaction includes an upfront payment of $1.1 billion, with up to $400 million in additional milestone payments tied to development progress. Closing is expected in the second half of 2026, pending regulatory approvals and other customary conditions.

ADCs work by pairing a targeting antibody with a cell-killing payload, allowing cancer-fighting compounds to be delivered more directly to tumor cells while limiting damage to healthy tissue.¹ Myricx has built its platform around a novel payload mechanism based on inhibition of an enzyme called N-myristoyltransferase, which plays a role in helping certain proteins function inside cells, including processes that cancer cells depend on to grow and survive. The company's 2 lead programs target the proteins B7-H3 and HER2, with potential applications across multiple solid tumor types.

Why Does the Payload Mechanism Matter?

Much of the current ADC landscape relies on a relatively narrow set of payload classes, including topoisomerase-1 inhibitors.¹ As these therapies have moved into broader clinical use, resistance to existing payload mechanisms has become a recognized limitation, one that can reduce durability of response and narrow the patient populations who benefit. Preclinical data cited by Novartis suggest the N-myristoyltransferase inhibitor payload retains activity in models resistant to topoisomerase-1 inhibitors, which, if confirmed in clinical development, would represent a meaningful expansion of options for patients who progress on currently available conjugates.

The appeal of a differentiated payload class extends beyond clinical mechanism.¹ Payload chemistry has direct implications for conjugation strategy, linker stability, and downstream process development, all of which shape how a candidate molecule scales from early-phase production to commercial manufacturing. A validated new payload platform, rather than an incremental modification of an existing one, opens design space for how future conjugates in this class might be constructed and produced.

What Does This Signal About Novartis’ Broader Strategy?

“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, president of Biomedical Research, Novartis, in a press release.¹ “Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism that could broaden the use of ADCs across multiple tumor settings. This proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients.”

Applied to ADCs, this suggests Novartis is positioning the Myricx payload not simply as an asset tied to 2 current programs, but as a platform that could, pending clinical validation, be paired with additional targeting antibodies over time.¹ That is a longer-term bet, and one that depends heavily on how the lead B7-H3 and HER2 programs perform in the clinic.

The deal also reflects continued consolidation activity in the ADC space, as larger pharmaceutical companies look to smaller, platform-focused biotechnology firms to fill gaps in payload diversity rather than building novel mechanisms internally.¹ This transaction is a reminder that payload innovation, not just antibody targeting, remains an active area of competitive differentiation, with direct downstream consequences for how these molecules will eventually be designed, produced, and scaled.

Is This Part of a Broader Pattern in Oncology Dealmaking?

The Myricx transaction fits within a wider run of payload-focused acquisitions across the industry in recent months.^2-4 In May, Gilead Sciences completed their acquisition of Tubulis, a German biotechnology company whose linker-payload technology and lead ovarian cancer asset expanded Gilead's conjugate capabilities.² That same month, Eli Lilly moved to acquire CrossBridge Bio, a preclinical company developing a dual-payload conjugate designed to combine 2 distinct mechanisms in a single molecule, an approach aimed at addressing resistance patterns similar to those cited in the Myricx deal.³

In June, GSK's acquisition of Nuvalent, though centered on lung cancer inhibitors, was framed partly around expanding use of GSK's own B7-H3 targeted conjugate, underscoring how even deals built around other assets are increasingly being positioned with conjugate strategy in mind.⁴

Taken together, these transactions suggest that payload and linker chemistry have become a primary point of competitive differentiation, a trend with direct consequences for how manufacturing and process development teams approach next-generation conjugate production.^2-4

References

1. Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients. Press release. Novartis. July 6, 2026. https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients
2. Gilead Sciences completes acquisition of Tubulis, further strengthening oncology portfolio. Press release. Gilead Sciences, Inc. May 20, 2026. https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-tubulis-further-strengthening-oncology-portfolio
3. CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload antibody-drug conjugates. Business Wire. April 14, 2026. https://www.businesswire.com/news/home/20260414133394/en/CrossBridge-Bio-Enters-an-Agreement-to-be-Acquired-by-Eli-Lilly-to-Advance-Next-Generation-Dual-Payload-Antibody-Drug-Conjugates
4. GSK enters agreement to acquire Nuvalent, Inc. Press Release. GSK June 9, 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc